A recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicity

Molecular Cancer Therapeutics

Volumn 12, Issue 1, 2013, Pages 48-57

  Weldon, John E ^a,b   Xiang, Laiman ^a   Zhang, Jingli ^a   Beers, Richard ^a   Walker, Dawn A ^a   Onda, Masanori ^a   Hassan, Raffit ^a   Pastan, Ira ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b TOWSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FURIN; GLYCYLGLYCYLSERINE; IMMUNOTOXIN; MESOTHELIN; NEUTRALIZING ANTIBODY; RECOMBINANT IMMUNOTOXIN; SOLVENT; SS1 LR GGS 8M IMMUNOTOXIN; SS1 LR GGS IMMUNOTOXIN; SS1 LR IMMUNOTOXIN; SS1P IMMUNOTOXIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CAPILLARY LEAK SYNDROME; CATALYSIS; CELL VIABILITY; CONTROLLED STUDY; DRUG ANTIGENICITY; DRUG BINDING; DRUG CYTOTOXICITY; DRUG HALF LIFE; FEMALE; HUMAN; HUMAN CELL; IMMUNOGENICITY; MAXIMUM TOLERATED DOSE; MESOTHELIOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DOMAIN; PROTEIN ENGINEERING; RAT;

AMINO ACID SUBSTITUTION; ANIMALS; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CAPILLARY LEAK SYNDROME; CELL LINE, TUMOR; FEMALE; GPI-LINKED PROTEINS; HALF-LIFE; HUMANS; INHIBITORY CONCENTRATION 50; MAXIMUM TOLERATED DOSE; MESOTHELIOMA; MICE; MICE, NUDE; MUTAGENESIS, SITE-DIRECTED; RATS; RATS, WISTAR; RECOMBINANT FUSION PROTEINS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84872578731     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-0336     Document Type: Article

References (50)

1. Kreitman RJ, Squires DR, Stetler-Stevenson M, Noel P, FitzGerald DJP, Wilson WH, et al. Phase I trial of recombinant immunotoxin RFB4 (dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol 2005;23:6719-29.
2. Kreitman RJ, Stetler-Stevenson M, Margulies I, Noel P, FitzGerald DJP, Wilson WH, et al. Phase II trial of recombinant immunotoxin RFB4 (dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J Clin Oncol 2009;27:2983-90.
3. Wayne AS, Kreitman RJ, Findley HW, Lew G, Delbrook C, Steinberg SM, et al. Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22- positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial. Clin Cancer Res 2010;16:1894-903.
4. Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, Stetler- Stevenson M, et al. Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol 2012;30:1822-8.
5. Hassan R, Bullock S, Premkumar A, Kreitman RJ, Kindler H, Willingham MC, et al. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patientswith mesothelin- expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res 2007;13:5144-9.
6. Kreitman RJ, Hassan R, Fitzgerald DJ, Pastan I. Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. Clin Cancer Res 2009;15:5274-9.
7. Hassan R, Sharon E, Schuler B, Mallory Y, Zhang J, Ling A, et al. Antitumor activity of SS1P with pemetrexed and cisplatin for newly diagnosed patients with advanced pleural mesothelioma and utility of serum mesothelin as a marker of tumor response [abstract]. In: Proceedings of the American Society of Clinical Oncology (ASCO) Annual Meeting Abstract; 2011 Jun 3-7; Chicago, IL
8. Sampson JH, Akabani G, Archer GE, Berger MS, Coleman RE, Freidman AH, et al. Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. Neuro Oncol 2008;10: 320-9.
9. Pai LH, Wittes R, Setser A, Willingham MC, Pastan I. Treatment of advanced solid tumors with immunotoxin LMB-1: an antibody linked to Pseudomonas exotoxin. Nat Med 1996;2:350-3.
10. Weldon JE, Pastan I. A guide to taming a toxin: recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer. FEBS J 2011;278:4683-700.
11. Seetharam S, Chaudhary VK, FitzGerald D, Pastan I. Increased cytotoxic activity of Pseudomonas exotoxin and two chimeric toxins ending in KDEL. J Biol Chem 1991;266:17376-81.
12. Du X, Ho M, Pastan I. New immunotoxins targeting CD123, a stem cell antigen on acute myeloid leukemia cells. J Immunother 2007;30: 607-13.
13. Rozemuller H, Chowdhury PS, Pastan I, Kreitman RJ. Isolation of new anti-CD30 scFvs from DNA-immunized mice by phage display and biologic activity of recombinant immunotoxins produced by fusion with truncated Pseudomonas exotoxin. Int J Cancer 2001; 92:861-70.
14. Kreitman RJ, Pastan I. Importance of the glutamate residue of KDEL in increasing the cytotoxicity of Pseudomonas exotoxin derivatives and for increased binding to the KDEL receptor. Biochem J 1995;307(Pt 1):29-37.
15. Salvatore G, Beers R, Margulies I, Kreitman RJ, Pastan I. Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display. Clin Cancer Res 2002;8:995-1002.
16. Decker T, Oelsner M, Kreitman RJ, Salvatorae G, Wang QC, Pastan I, et al. Induction of caspase-dependent programmed cell death in B-cell chronic lymphocytic leukemia by anti-CD22 immunotoxins. Blood 2004;103:2718-26.
17. Johannes L, Decaudin D. Protein toxins: intracellular trafficking for targeted therapy. Gene Ther 2005;12:1360-8.
18. Fitzgerald D. Why toxins! Semin Cancer Biol 1996;7:87-95.
19. Weldon JE, Xiang L, Chertov O, Margulies I, Kreitman RJ, FitzGerald DJ, et al. A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity. Blood 2009;113:3792-800.
20. Onda M, Nagata S, FitzGerald DJ, Beers R, Fisher RJ, Vincent JJ, et al. Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients. J Immunol 2006;177:8822-34.
21. Hansen JK, Weldon JE, Xiang L, Beers R, Onda M, Pastan I. A recombinant immunotoxin targeting CD22 with low immunogenicity, low nonspecific toxicity, and high antitumor activity in mice. J Immunother 2010;33:297-304.
22. Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A 1996;93:136-40.
23. Frierson HF Jr, Moskaluk CA, Powell SM, Zhang H, Cerilli LA, Stoler MH, et al. Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas. Hum Pathol 2003;34:605-9.
24. O'Reilly MK, Tian H, Paulson JC. CD22 is a recycling receptor that can shuttle cargo between the cell surface and endosomal compartments of B cells. J Immunol 2011;186:1554-63.
25. Fujita M, Kinoshita T. GPI-anchor remodeling: potential functions of GPI-anchors in intracellular trafficking and membrane dynamics. Biochim Biophys Acta 2012;1821:1050-8.
26. Pastan I, Beers R, Bera TK. Recombinant immunotoxins in the treatment of cancer. Methods Mol Biol 2004;248:503-18.
27. Chowdhury PS, Viner JL, Beers R, Pastan I. Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity. Proc Natl Acad Sci U S A 1998;95: 669-74.
28. Ho M, Hassan R, Zhang J, Wang QC, Onda M, Bera T, et al. Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients. Clin Cancer Res 2005;11:3814-20.
29. Xiang X, Phung Y, Feng M, Nagashima K, Zhang J, Broaddus VC, et al. The development and characterization of a human mesothelioma in vitro 3D model to investigate immunotoxin therapy. PLoS ONE 2011;6: e14640.
30. Bang S, Nagata S, Onda M, Kreitman RJ, Pastan I. HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity. Clin Cancer Res 2005;11: 1545-50.
31. Siegall CB, Liggitt D, Chace D, Tepper MA, Fell HP. Prevention of immunotoxin-mediated vascular leak syndrome in rats with retention of antitumor activity. Proc Natl Acad Sci U S A 1994; 91:9514-8.
32. Onda M, Beers R, Xiang L, Lee B, Weldon JE, Kreitman RJ, et al. Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes. Proc Natl Acad Sci U S A 2011;108:5742-7.
33. Chowdhury PS, Pastan I. Improving antibody affinity by mimicking somatic hypermutation in vitro. Nat Biotechnol 1999;17: 568-72.
34. Reiter Y, Pastan I. Antibody engineering of recombinant Fv immunotoxin for improved targeting of cancer: disulfide-stabilized Fv immunotoxins. Clin Cancer Res 1996;2:245-52.
35. Wedekind JE, Trame CB, Dorywalska M, Koehl P, Raschke TM, McKee M, et al. Refined crystallographic structure of Pseudomonas aeruginosa exotoxin A and its implications for the molecular mechanism of toxicity. J Mol Biol 2001;314:823-37.
36. Thomas G. Furin at the cutting edge: from protein traffic to embryogenesis and disease. Nat Rev Mol Cell Biol 2002;3:753-66.
37. Morlon-Guyot J, Méré J, Bonhoure A, Beaumelle B. Processing of Pseudomonas aeruginosa exotoxin A is dispensable for cell intoxication. Infect Immun 2009;77:3090-9.
38. Ornatowski W, Poschet JF, Perkett E, Taylor-Cousar JL, Deretic V. Elevated furin levels in human cystic fibrosis cells result in hypersusceptibility to exotoxin A-induced cytotoxicity. J Clin Invest 2007;117: 3489-97.
39. Chiron MF, Fryling CM, FitzGerald D. Furin-mediated cleavage of Pseudomonas exotoxin-derived chimeric toxins. J Biol Chem 1997;272:31707-11.
40. Moehring JM, Inocencio NM, Roertson BJ, Moehring TJ. Expression of mouse furin in a Chinese hamster cell resistant to Pseudomonas exotoxin A and viruses complements the genetic lesion. J Biol Chem 1993;18:2590-4.
41. Onda M, Willingham M, Wang QC, Kreitman RJ, Tsutsumi Y, Nagata S, et al. Inhibition of TNF-alpha produced by Kupffer cells protects against the nonspecific liver toxicity of immunotoxin anti-Tac(Fv)- PE38, LMB-2. J Immunol 2000;165:7150-6.
42. Druey KM, Greipp PR. Narrative review: the systemic capillary leak syndrome. Ann Intern Med 2010;153:90-8.
43. Baluna R, Rizo J, Gordon BE, Ghetie V, Vitetta ES. Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome. Proc Natl Acad Sci U S A 1999;96:3957-62.
44. Siegall CB, Liggitt D, Chace D, Mixan B, Sugai J, Davidson T, et al. Characterization of vascular leak syndrome induced by the toxin component of Pseudomonas exotoxin-based immunotoxins and its potential inhibition with nonsteroidal anti-inflammatory drugs. Clin Cancer Res 1997;3:339-45.
45. Brenner BM, Hostetter TH, Humes HD. Glomerular permselectivity: barrier function based on discrimination of molecular size and charge. Am J Physiol 1978;234:F455-60.
46. Kreitman RJ, Pastan I. Accumulation of a recombinant immunotoxin in a tumor in vivo: fewer than 1000 molecules per cell are sufficient for complete responses. Cancer Res 1998;58: 968-75.
47. Traini R, Kreitman RJ. Renal excretion of recombinant immunotoxins containing Pseudomonas exotoxin. Bioconjug Chem 2011;22:736-40.
48. Boron WF, Boulpaep EF, editors. Medical physiology: a cellular and molecular approach. 2nd ed. Philadelphia, PA: Elsevier/Saunders; 2009.
49. Bera TK, Pastan I. Comparison of recombinant immunotoxins against LeY antigen expressing tumor cells: influence of affinity, size, and stability. Bioconjug Chem 1998;9:736-43.
50. Zhang Y, Hansen JK, Xiang L, Kawa S, Onda M, Ho M, et al. A flow cytometry method to quantitate internalized immunotoxins shows that taxol synergistically increases cellular immunotoxins uptake. Cancer Res 2010;70:1082-9.